Author: admin

Spell Painting LLC Expands Professional Painting Services in Lafayette, Indiana

Spell Painting LLC Expands Professional Painting Services in Lafayette, Indiana
Spell Painting LLC, a trusted provider of high-quality painting services, announces the expansion of its residential and commercial offerings to serve homeowners and businesses across Lafayette, Indiana. Specializing in Cabinet Painting, Commercial Painting, and Exterior Home Painting, the company aims to deliver exceptional results that enhance interior and exterior spaces.

The painting experts at Spell Painting LLC bring years of experience and a commitment to customer satisfaction, ensuring every project meets the highest standards. The company’s Cabinet Painting Lafayette service transforms outdated or worn cabinets into fresh, vibrant home elements. Whether for kitchens, bathrooms, or other spaces, this service offers a cost-effective solution for upgrading the look of cabinetry without the need for complete replacements.

For businesses, Spell Painting LLC provides Commercial Painting Lafayette services that help improve the appearance and professionalism of workspaces. The commercial painting team understands the importance of delivering timely, non-intrusive solutions that keep businesses running smoothly. Spell Painting LLC is prepared to meet the unique needs of every commercial project, ensuring a seamless process from start to finish.

The Exterior Home Painting Lafayette service offers homeowners a way to revitalize the look of their property. Spell Painting LLC uses high-quality materials and advanced painting techniques to ensure exterior surfaces withstand the elements while maintaining a polished, refreshed appearance.

About Spell Painting LLC

Spell Painting LLC is a premier painting service dedicated to transforming spaces with precision and artistry. Specializing in residential and commercial projects, our skilled team ensures high-quality finishes using top-notch materials. With a commitment to customer satisfaction, we bring your vision to life, making every project a masterpiece.

Media Contact
Company Name: Spell Painting LLC
Contact Person: Josh Spell
Email: Send Email
Address:316 Adry Ln
City: Youngsville
State: LA
Country: United States
Website: https://spellpainting.com/

Polymyositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas

The Key Polymyositis Companies in the market include – Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Pfizer, Bristol-Myers Squibb, and others.

 

DelveInsight’s “Polymyositis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Polymyositis, historical and forecasted epidemiology as well as the Polymyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Polymyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polymyositis Market Forecast

 

Some of the key facts of the Polymyositis Market Report: 

  • The Polymyositis market size was valued approximately ~USD 114 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In 2023, Germany had the largest Polymyositis market size among EU countries, valued at approximately USD 6 million, while Spain recorded the smallest market size at around USD 2 million.

  • The anticipated introduction of new therapies, including Anifrolumab (SAPHNELO), PF-06823859, and Enpatoran (M5049), among others, is expected to drive changes in the total market size of Polymyositis in the coming years.

  • In 2023, the United States had the largest market size for Polymyositis among the 7MM, reaching approximately USD 86 million. This figure is anticipated to grow at a compound annual growth rate (CAGR) of 15.8% throughout the forecast period.

  • According to DelveInsight’s analysis, the estimated total number of diagnosed prevalent cases of Polymyositis in the 7MM was approximately 80,000 in 2023.

  • In 2023, Germany had the highest number of diagnosed prevalent cases of Polymyositis among European countries, with around 9,000 cases, followed by France with approximately 7,000 cases. In contrast, Spain had the lowest prevalent population, with about 3,000 cases.

  • In 2023, Japan reported around 12,000 diagnosed prevalent cases of Polymyositis, representing roughly 16% of the total cases across the 7MM.

  • According to DelveInsight’s analysis, females in Japan were more commonly affected by Polymyositis than males, with around 9,000 female cases compared to 3,000 male cases in 2023.

  • Key Polymyositis Companies: Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Pfizer, Bristol-Myers Squibb, and others

  • Key Polymyositis Therapies: Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others

  • The Polymyositis epidemiology based on gender analyzed that Polymyositis affects females more as compared to males

  • The Polymyositis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Polymyositis pipeline products will significantly revolutionize the Polymyositis market dynamics.

 

Polymyositis Overview

Polymyositis is a rare, chronic inflammatory muscle disease characterized by muscle weakness and inflammation. It belongs to a group of diseases called inflammatory myopathies and primarily affects the skeletal muscles, which are responsible for movement.

 

Get a Free sample for the Polymyositis Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/polymyositis-market

 

Polymyositis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Polymyositis Epidemiology Segmentation:

The Polymyositis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Polymyositis

  • Prevalent Cases of Polymyositis by severity

  • Gender-specific Prevalence of Polymyositis

  • Diagnosed Cases of Episodic and Chronic Polymyositis

 

Download the report to understand which factors are driving Polymyositis epidemiology trends @ Polymyositis Epidemiology Forecast

 

Polymyositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polymyositis market or expected to get launched during the study period. The analysis covers Polymyositis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Polymyositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Polymyositis Therapies and Key Companies

  • Efgartigimod: Argenx

  • PF1801: Immunoforge Co. Ltd.

  • tocilizumab: Chester Oddis

  • KZR-616: Kezar Life Sciences, Inc.

  • Adrenocorticotropic Hormone Gel: Mallinckrodt

  • M5049 high dose: Merck KGaA

  • Tacrolimus: Astellas Pharma Inc

  • Rituximab: Genentech

  • Froniglutide: Immunoforge Co. Ltd.

  • PF-06823859: Pfizer

  • Abatacept subcutaneous: Bristol-Myers Squibb

 

Discover more about therapies set to grab major Polymyositis market share @ Polymyositis Treatment Landscape

 

Scope of the Polymyositis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Polymyositis Companies: Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas Pharma Inc, Genentech, Pfizer, Bristol-Myers Squibb, and others

  • Key Polymyositis Therapies: Efgartigimod, PF1801, tocilizumab, KZR-616, Adrenocorticotropic Hormone Gel, M5049 high dose, Tacrolimus, Rituximab, Froniglutide, PF-06823859, Abatacept subcutaneous, and others

  • Polymyositis Therapeutic Assessment: Polymyositis current marketed and Polymyositis emerging therapies

  • Polymyositis Market Dynamics: Polymyositis market drivers and Polymyositis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Polymyositis Unmet Needs, KOL’s views, Analyst’s views, Polymyositis Market Access and Reimbursement 

 

To know more about Polymyositis companies working in the treatment market, visit @ Polymyositis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Polymyositis Market Report Introduction

2. Executive Summary for Polymyositis

3. SWOT analysis of Polymyositis

4. Polymyositis Patient Share (%) Overview at a Glance

5. Polymyositis Market Overview at a Glance

6. Polymyositis Disease Background and Overview

7. Polymyositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Polymyositis 

9. Polymyositis Current Treatment and Medical Practices

10. Polymyositis Unmet Needs

11. Polymyositis Emerging Therapies

12. Polymyositis Market Outlook

13. Country-Wise Polymyositis Market Analysis (2020–2034)

14. Polymyositis Market Access and Reimbursement of Therapies

15. Polymyositis Market Drivers

16. Polymyositis Market Barriers

17.  Polymyositis Appendix

18. Polymyositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Polymyositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Argenx, Immunoforge Co. Ltd., Chester Oddis, Kezar Life Sciences, Inc., Mallinckrodt, Merck KGaA, Astellas

Gastroparesis Market Expected to Experience Major Growth by 2034, According to DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma

The Key Gastroparesis Companies in the market include – Evoke Pharma, Vanda Pharmaceuticals, CinDome Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma, Inc., GlaxoSmithKline, Chugai Pharma, Neurogastrx, Inc., Targacept Inc., Takeda, Millennium Pharma, Eli Lilly and Company, Forest Laboratories, and others.

 

DelveInsight’s “Gastroparesis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Gastroparesis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroparesis Market Forecast

 

Some of the key facts of the Gastroparesis Market Report: 

  • The Gastroparesis market size was valued ~USD 240 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In May 2024, CinDome Pharma has successfully raised $40 million in a Series B financing extension to further the development of deudomperidone (CIN-102) as a potential treatment for chronic gastroparesis. This additional funding came from existing investors, including Perceptive Advisors and CinRx Pharma. With this new investment, the total capital raised in the Series B round has reached $59 million. The funds will support the ongoing Phase II envision3D study of deudomperidone in adults with diabetic gastroparesis and prepare the company for upcoming registrational trials.

  • In December 2023, Vanda Pharmaceuticals reported that the US FDA has approved the submission of Vanda’s New Drug Application (NDA) for tradipitant to address symptoms associated with gastroparesis.

  • In November 2023, Evoke Pharma disclosed that the United States Patent and Trademark Office (USPTO) has granted US Patent No. 11,813,231, concerning the company’s FDA-approved nasal formulation of metoclopramide, known as GIMOTI. This patent provides coverage for the product until 2029.

  • In April 2023, CinRx Pharma’s subsidiary, CinDome Pharma, administered the initial dose to the first patient in its Phase II envision3D trial of deudomperidone (CIN-102) for the prolonged management of diabetic gastroparesis in the US. This placebo-controlled, randomized, multicenter, double-blind study aims to assess the safety and effectiveness of deudomperidone, which functions as a dopamine 2/3 antagonist with prokinetic and antiemetic properties.

  • Several emerging therapies for Gastroparesis, including Tradipitant, CIN-102, PCS12852, and others, are currently undergoing late-stage clinical development.

  • In 2023, among the seven major markets (7MM), the United States had the highest number of diagnosed prevalent cases of gastroparesis, totaling approximately 720,000 cases.

  • In 2023, the United States had the highest number of prevalent cases of Gastroparesis-like symptoms among the 7MM, with an estimated 4.5 million cases.

  • In the United States, the age group with the highest number of specific cases in 2023 was 65 years and older, followed by the 48-57 age group. Conversely, the age group with the fewest specific cases was observed among individuals aged 18-27 years.

  • Gastroparesis primarily affects women, with approximately 68.5% of diagnosed patients being females, while males account for only about 31.5% of diagnosed cases.

  • Key Gastroparesis Companies: Evoke Pharma, Vanda Pharmaceuticals, CinDome Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma, Inc., GlaxoSmithKline, Chugai Pharma, Neurogastrx, Inc., Targacept Inc., Takeda, Millennium Pharma, Eli Lilly and Company, Forest Laboratories, and others

  • Key Gastroparesis Therapies: GIMOTI (metoclopramide) Nasal Spray, VLY-686 (tradipitant), CIN-102 (deudomperidone), Tradipitant, Naronapride, velusetrag, CNSA-001, CIN-102, Camicinal, GM-611, GSK962040, NG101, TC-6499, TAK-954, TAK-906 Maleate, tadalafil, Itopride, and others

  • The Gastroparesis epidemiology based on gender analyzed that Gastroparesis cases were higher in females in comparison to males, in all the 7MM countries

  • The Gastroparesis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroparesis pipeline products will significantly revolutionize the Gastroparesis market dynamics.

 

Gastroparesis Overview

Gastroparesis is a medical condition characterized by delayed emptying of the stomach contents into the small intestine, without the presence of any mechanical obstruction. This delay in gastric emptying can lead to symptoms such as nausea, vomiting, bloating, early satiety (feeling full quickly after eating), abdominal pain, and a lack of appetite.

 

Get a Free sample for the Gastroparesis Market Report: 

https://www.delveinsight.com/report-store/gastroparesis-market

 

Gastroparesis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Gastroparesis Epidemiology Segmentation:

The Gastroparesis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Gastroparesis

  • Prevalent Cases of Gastroparesis by severity

  • Gender-specific Prevalence of Gastroparesis

  • Diagnosed Cases of Episodic and Chronic Gastroparesis

 

Download the report to understand which factors are driving Gastroparesis epidemiology trends @ Gastroparesis Epidemiology Forecast

 

Gastroparesis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroparesis market or expected to get launched during the study period. The analysis covers Gastroparesis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroparesis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Gastroparesis Therapies and Key Companies

  • GIMOTI (metoclopramide) Nasal Spray: Evoke Pharma

  • VLY-686 (tradipitant): Vanda Pharmaceuticals

  • CIN-102 (deudomperidone): CinDome Pharm

  • Tradipitant: Vanda Pharmaceuticals

  • Naronapride: Dr. Falk Pharma GmbH

  • velusetrag: Alfasigma S.p.A.

  • CNSA-001: PTC Therapeutics

  • CIN-102: CinDome Pharma, Inc.

  • Camicinal: GlaxoSmithKline

  • GM-611: Chugai Pharma

  • GSK962040: GlaxoSmithKline

  • NG101: Neurogastrx, Inc.

  • TC-6499: Targacept Inc.

  • TAK-954: Takeda

  • TAK-906 Maleate: Millennium Pharma

  • tadalafil: Eli Lilly and Company

  • Itopride: Forest Laboratories

 

Discover more about therapies set to grab major Gastroparesis market share @ Gastroparesis Treatment Market

 

Gastroparesis Market Strengths

  • The prevalence of gastroparesis is rising, especially among children and minority groups, conceivably due to a rise in diabetes around the world.  

  • Several investigational therapies, such as new dopamine receptor agonists, 5-HT4 receptor agonists, and NK-1R antagonists, are being studied in different clinical trials, which are likely to bring potential therapies for the treatment of gastroparesis.

 

Gastroparesis Market Opportunities

  • Patients with drug-refractory gastroparesis can benefit from the help of new interventions such as pyloromyotomy and pyloroplasty. The combination of gastric electrical stimulation with pyloroplasty also holds promise as a potential treatment for this specific patient group.  

  • Understanding the neuropharmacological aspects of gastroparesis represents an opportunity for the development of targeted treatments, enhancing precision in addressing specific components of the gastroparesis symptom complex.

 

Scope of the Gastroparesis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Gastroparesis Companies: Evoke Pharma, Vanda Pharmaceuticals, CinDome Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma, Inc., GlaxoSmithKline, Chugai Pharma, Neurogastrx, Inc., Targacept Inc., Takeda, Millennium Pharma, Eli Lilly and Company, Forest Laboratories, and others

  • Key Gastroparesis Therapies: GIMOTI (metoclopramide) Nasal Spray, VLY-686 (tradipitant), CIN-102 (deudomperidone), Tradipitant, Naronapride, velusetrag, CNSA-001, CIN-102, Camicinal, GM-611, GSK962040, NG101, TC-6499, TAK-954, TAK-906 Maleate, tadalafil, Itopride, and others

  • Gastroparesis Therapeutic Assessment: Gastroparesis current marketed and Gastroparesis emerging therapies

  • Gastroparesis Market Dynamics: Gastroparesis market drivers and Gastroparesis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Gastroparesis Unmet Needs, KOL’s views, Analyst’s views, Gastroparesis Market Access and Reimbursement 

 

To know more about Gastroparesis companies working in the treatment market, visit @ Gastroparesis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Gastroparesis Market Report Introduction

2. Executive Summary for Gastroparesis

3. SWOT analysis of Gastroparesis

4. Gastroparesis Patient Share (%) Overview at a Glance

5. Gastroparesis Market Overview at a Glance

6. Gastroparesis Disease Background and Overview

7. Gastroparesis Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroparesis 

9. Gastroparesis Current Treatment and Medical Practices

10. Gastroparesis Unmet Needs

11. Gastroparesis Emerging Therapies

12. Gastroparesis Market Outlook

13. Country-Wise Gastroparesis Market Analysis (2020–2034)

14. Gastroparesis Market Access and Reimbursement of Therapies

15. Gastroparesis Market Drivers

16. Gastroparesis Market Barriers

17.  Gastroparesis Appendix

18. Gastroparesis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastroparesis Market Expected to Experience Major Growth by 2034, According to DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma

Miller & Smith Celebrates Successful Closeout of Patapsco Crossing in Ellicott City, Maryland

“Stand out with these luxury homes at Patasco Crossing”
Miller & Smith, a prominent homebuilder celebrating its 60th year, has successfully completed the Patapsco Crossing community in partnership with Pleasants Development. This luxury home community, designed with flexibility in mind, caters to diverse buyers, including multi-generational families.

Ellicott City, MD – Oct 7, 2024 – Miller & Smith, a leading local homebuilder celebrating its 60th year in business, proudly announces the successful closeout of another luxury home community at Patapsco Crossing. This distinctive community is designed for a diverse market, catering to the unique needs of buyers, including multi-generational families, by offering thoughtfully designed homes with exceptional flexibility built into the plans. 

Patapsco Crossing, developed in partnership with longtime collaborator Pleasants Development, who also is celebrating its 60th year, exemplifies the synergy and shared commitment to excellence between the two legacy companies.

“We’ve had a number of projects in Maryland, but it’s been a few years since we had something in Howard County. Howard County neighborhoods have always performed well for us, as there is a strong need for housing in the area,” says Bob Spalding, Miller & Smith’s Vice President – Land. “Partnering with Pleasants Development, the developer of Patapsco Crossing, was a natural fit given our long-standing relationship.”

Flexibility was a key focus of this project to fulfill a varied set of requirements from a diverse homebuyer demographic. This adaptability applied to a brand-new multi-generational home design, but also included offering options from three car garages to outside access from basements for homes without a standard walkout condition, catering to diverse buyer needs.

“We made sure to build in the flexibility to allow homebuyers to have choices,” Spalding said. “Our challenge was to ensure that the site plan could accommodate these options and we successfully made that happen.”

Patapsco Crossing has met a significant demand for multi-generational living, offering options like first-floor suites for aging in place and accommodating families who want to live together across multiple generations. “We’ve seen many families take advantage of this, allowing parents and grandparents to live with their children and grandchildren, fostering stronger family bonds.”

The community’s location, became another natural asset, nestled among parks with easy access to major commuter routes. Within moments of Patapsco Valley State Park or Downton Ellicott City, Patapsco Crossing’s location became another valuable draw for families from all walks of life.

“It’s always fun and rewarding to see people making their biggest investment and raising their families in a place you helped design and develop,” says Spalding. “There are always thousands of little things we try to solve to make sure their home is everything they intended and it’s always so fulfilling when it turns out to be a place where people love to raise their families.”

Founded in 1964, Miller & Smith is a privately owned builder and developer active in both residential and commercial real estate. Known for creating innovative and imaginative homes and communities, Miller & Smith is one of the largest private homebuilders in the Washington, DC metropolitan region. The company has built more than 6,500 single-family homes, 10,000 townhomes, and 2,100 condominiums and developed 18,500 home sites in 150 communities throughout Maryland, Virginia, and Delaware. Miller & Smith is headquartered in McLean, Virginia.

For more information, visit MillerandSmith.com.

Media Contact
Company Name: Miller and Smith
Contact Person: Sara Buehl
Email: Send Email
Phone: 703-975-2982
City: Vienna
State: VA
Country: United States
Website: https://millerandsmith.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Miller & Smith Celebrates Successful Closeout of Patapsco Crossing in Ellicott City, Maryland

Catheter Related Bloodstream Infections Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Xellia Pharma, Pfizer, Glenmark Pharma, Fresenius Medical Care

The Key Catheter Related Bloodstream Infections Companies in the market include – CorMedix, Xellia Pharmaceuticals Ltd., Pfizer, Glenmark Pharmaceuticals Ltd., Fresenius Medical Care, CorMedix, Inc., TauroPhar GmbH, Geistlich Pharma, Citus Pharmaceuticals, AstraZeneca, Merck & Co., Inc., and others.

 

DelveInsight’s “Catheter Related Bloodstream Infections Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Catheter Related Bloodstream Infections, historical and forecasted epidemiology as well as the Catheter Related Bloodstream Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Catheter Related Bloodstream Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Catheter Related Bloodstream Infections Market Forecast

 

Some of the key facts of the Catheter Related Bloodstream Infections Market Report: 

  • The Catheter Related Bloodstream Infections market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In May 2024, Citius Pharmaceuticals reported positive topline results from its pivotal Phase III clinical trial of Mino-Lok. The study achieved its primary endpoint, showing a statistically significant improvement in time to failure events in patients treated with Mino-Lok compared to those in the control group receiving clinician-directed anti-infective lock solutions.

  • As per the DelveInsight’s estimates, the total incident population of CRBSI in the 7MM was found to be around 674,000 in 2020, which is anticipated to increase in the forecasted period

  • The estimates show a higher incidence of Catheter Related Bloodstream Infections in the US with about 331,000 cases in 2020

  • As per the analysis, in the US, the incidence of Gram-positive bacteria is more than Gram negative bacteria and very few are affected with candida species (fungi)

  • Among EU4 and the UK, Germany accounted for the highest incident cases of Catheter Related Bloodstream Infections with more than 62,000 cases in 2020. Whereas, the least number of incident cases was contributed by Spain with about 17,000 cases

  • Key Catheter Related Bloodstream Infections Companies: CorMedix, Xellia Pharmaceuticals Ltd., Pfizer, Glenmark Pharmaceuticals Ltd., Fresenius Medical Care, CorMedix, Inc., TauroPhar GmbH, Geistlich Pharma, Citus Pharmaceuticals, AstraZeneca, Merck & Co., Inc., and others

  • Key Catheter Related Bloodstream Infections Therapies: DEFENCATH, Mino-Lok, Neutrolin, Daptomycin, Linezolid, and others

  • The Catheter Related Bloodstream Infections epidemiology based on gender analyzed that the incidence of Catheter Related Bloodstream Infections is found to be prominent in Non-ICU settings

  • The Catheter Related Bloodstream Infections market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Catheter Related Bloodstream Infections pipeline products will significantly revolutionize the Catheter Related Bloodstream Infections market dynamics.

 

Catheter Related Bloodstream Infections Overview

Catheter-related bloodstream infection (CRBSI) is defined as the presence of bacteremia originating from an intravenous catheter. It is one of the most frequent, lethal, and costly complications of central venous catheterization and also the most common cause of nosocomial bacteremia.

 

Get a Free sample for the Catheter Related Bloodstream Infections Market Report:

https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market

 

Catheter Related Bloodstream Infections Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Catheter Related Bloodstream Infections Epidemiology Segmentation:

The Catheter Related Bloodstream Infections market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Catheter Related Bloodstream Infections

  • Prevalent Cases of Catheter Related Bloodstream Infections by severity

  • Gender-specific Prevalence of Catheter Related Bloodstream Infections

  • Diagnosed Cases of Episodic and Chronic Catheter Related Bloodstream Infections

 

Download the report to understand which factors are driving Catheter Related Bloodstream Infections epidemiology trends @ Catheter Related Bloodstream Infections Epidemiology Forecast

 

Catheter Related Bloodstream Infections Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Catheter Related Bloodstream Infections market or expected to get launched during the study period. The analysis covers Catheter Related Bloodstream Infections market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Catheter Related Bloodstream Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Catheter Related Bloodstream Infections Therapies and Key Companies

  • DEFENCATH: CorMedix

  • Mino-Lok: Citius Pharmaceutical

  • Neutrolin: CorMedix

  • Daptomycin: Cubist Pharma

  • Linezolid: Pfizer

 

Discover more about therapies set to grab major Catheter Related Bloodstream Infections market share @ Catheter Related Bloodstream Infections Treatment Market

 

Scope of the Catheter Related Bloodstream Infections Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Catheter Related Bloodstream Infections Companies: CorMedix, Xellia Pharmaceuticals Ltd., Pfizer, Glenmark Pharmaceuticals Ltd., Fresenius Medical Care, CorMedix, Inc., TauroPhar GmbH, Geistlich Pharma, Citus Pharmaceuticals, AstraZeneca, Merck & Co., Inc., and others

  • Key Catheter Related Bloodstream Infections Therapies: DEFENCATH, Mino-Lok, Neutrolin, Daptomycin, Linezolid, and others

  • Catheter Related Bloodstream Infections Therapeutic Assessment: Catheter Related Bloodstream Infections current marketed and Catheter Related Bloodstream Infections emerging therapies

  • Catheter Related Bloodstream Infections Market Dynamics: Catheter Related Bloodstream Infections market drivers and Catheter Related Bloodstream Infections market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Catheter Related Bloodstream Infections Unmet Needs, KOL’s views, Analyst’s views, Catheter Related Bloodstream Infections Market Access and Reimbursement 

 

To know more about Catheter Related Bloodstream Infections companies working in the treatment market, visit @ Catheter Related Bloodstream Infections Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Catheter Related Bloodstream Infections Market Report Introduction

2. Executive Summary for Catheter Related Bloodstream Infections

3. SWOT analysis of Catheter Related Bloodstream Infections

4. Catheter Related Bloodstream Infections Patient Share (%) Overview at a Glance

5. Catheter Related Bloodstream Infections Market Overview at a Glance

6. Catheter Related Bloodstream Infections Disease Background and Overview

7. Catheter Related Bloodstream Infections Epidemiology and Patient Population

8. Country-Specific Patient Population of Catheter Related Bloodstream Infections 

9. Catheter Related Bloodstream Infections Current Treatment and Medical Practices

10. Catheter Related Bloodstream Infections Unmet Needs

11. Catheter Related Bloodstream Infections Emerging Therapies

12. Catheter Related Bloodstream Infections Market Outlook

13. Country-Wise Catheter Related Bloodstream Infections Market Analysis (2020–2034)

14. Catheter Related Bloodstream Infections Market Access and Reimbursement of Therapies

15. Catheter Related Bloodstream Infections Market Drivers

16. Catheter Related Bloodstream Infections Market Barriers

17.  Catheter Related Bloodstream Infections Appendix

18. Catheter Related Bloodstream Infections Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Catheter Related Bloodstream Infections Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Xellia Pharma, Pfizer, Glenmark Pharma, Fresenius Medical Care

Volleyball Season Continues to Heat Up in Dubai with Esperia Volleyball Academy

As the summer heat begins to subside in Dubai, the passion for volleyball remains as strong as ever. Esperia Volleyball Academy is thrilled to announce a variety of exciting programs and activities to keep the volleyball spirit alive throughout the year.From indoor leagues and kids’ camps to beach volleyball and private training, Esperia Volleyball Academy offers something for everyone. Whether someone is a seasoned player or just starting out, there are ample opportunities to improve skills, meet new people, and have fun.Key Highlights:

–  Volleyball Kids’ Camps: The Volleyball Kids’ Camps are crafted to introduce young players to the sport in a dynamic and engaging environment. These camps focus on fundamental skills, teamwork, and sportsmanship, ensuring children have fun while learning the basics of volleyball. Learn more about the kids’ camps.

–  Volleyball Training for Kids: Tailored for various skill levels, the Volleyball Training for Kids provides targeted instruction to help young athletes refine their techniques, improve game performance, and build confidence on the court. Sessions are designed to cater to both beginners and advanced players.

–  Volleyball Classes: The Volleyball Classes offer structured training for players of all ages and skill levels. From introductory lessons for beginners to advanced drills for seasoned players, these classes are designed to enhance technical skills, tactical understanding, and overall game performance. Explore volleyball classes.

–  Volleyball Activities: Engage in a wide array of Volleyball Activities, including competitive adult leagues, casual social matches, and personalized private training sessions. Whether looking to compete, socialize, or receive one-on-one coaching, there are options to suit diverse needs.

–  Court Rentals: Experience the flexibility of renting indoor or beach volleyball courts at multiple locations across Dubai. Ideal for personal play, team practice, or hosting events, the courts provide a unique and enjoyable setting for all volleyball needs.

–  Indoor Volleyball: Play volleyball in a controlled indoor environment, which offers the advantage of consistent conditions for practice and games regardless of weather. This setting is perfect for focusing on technique and strategy.

–  Beach Volleyball: Enjoy the vibrant atmosphere of beach volleyball under the Dubai sun. The beach volleyball sessions are great for social play, casual matches, or simply enjoying a game by the sea.

–  Funvolley Games: Participate in Funvolley Games, which are designed to maximize enjoyment and community engagement. These recreational games are perfect for players looking to have fun, meet new people, and enjoy the sport in a relaxed setting. Join Funvolley Games.

–  Fitness on the Beach (Sandfit): Combine a love for volleyball with fitness through Sandfit, the beach-based fitness program. Sandfit integrates volleyball drills with challenging physical workouts, providing a comprehensive fitness experience while taking advantage of Dubai’s beautiful beaches. Find out more about Sandfit.

Esperia Volleyball Academy is committed to providing a welcoming and inclusive environment for volleyball enthusiasts of all ages and skill levels. Joining this academy reveals why volleyball is the perfect sport for year-round enjoyment in Dubai.

For more information and to register, please visit Esperia Volleyball Academy or contact them via the following:

–  Whatsapp / Call: 800865539

–  Email: fly@volley.ae

Media Contact
Company Name: Esperia Volleyball academy
Contact Person: Eva
Email: Send Email
Country: United Arab Emirates
Website: https://www.volley.ae/

“Poems of Inspiration: A Daily Dose of Self-Motivation” by Rodrick Walters Reshapes Lives with Words

In a world where motivation and inspiration are in constant demand, Rodrick Walters’ latest book, “Poems of Inspiration: A Daily Dose of Self-Motivation” published by Olympus Story House, contains lively poems that can motivate and inspire readers to achieve their objectives.

Rodrick Walters puts his several years as an entrepreneur, speaker, and pastor into practice as he announces the introduction of the new “Poems of Inspiration: A Daily Dose of Self-Motivation.” Through his poems, he summons the readers to act and discover their abilities and embrace the, at times, challenging path in their journey towards self-development.

“Poems of Inspiration” speaks to everyone who wants to embrace the mindset of the fulfilled and successful. The author gives readers an efficient yet intense approach. His poems are not only art but a way of thinking. Each poem is written to acknowledge the challenges one encounters in the journey of life. The reader is presented with the choice to either be a victim of or to become a victor over those challenges.

The book’s potency is manifested in its straightforwardness and Walters’ evident passion for helping others. His poems are profound and clear in their intent to effect change. This characteristic makes this book the perfect additional resource for reflection.

Literary critics and supporters have complimented Walters’ work for its ability to establish a connection with the reader. Pacific Book Review stressed the book’s “basic message of hope and inspiration,” calling it a “literary salve” that is both “current and timeless.” 

“Rodrick is not only a motivational speaker but is also a motivational doer. I expect great things from him.” – Dr. Willie Jolley, Awarding-Winning Hall of Fame Speaker and Bestselling Author. 

“Very eloquently spoken. I was very impressed with your story of overcoming so many obstacles to become the talented communicator you are today.” – Bob Losure, CNN Anchor and Bestselling Author.

Rodrick Walters invites readers to journey through the pages of his book, uncovering the tools necessary for personal transformation and the courage to take that “one extra step” toward their dreams.

For more information about “Poems of Inspiration: A Daily Dose of Self-Motivation” and to purchase a copy, individuals can explore Olympus Story House website.

Media Contact
Company Name: Olympus Story House
Contact Person: Sophie Jenkins
Email: Send Email
Country: United States
Website: https://www.olympusstoryhouse.com/

Red Box Restoration Launches New Website, Showcasing Premier Custom Car Restoration Services in Austin

Red Box Restoration, Austin’s premier custom car restoration and reconditioning shop, is proud to announce the launch of its brand-new website. The revamped online presence aims to provide a more comprehensive, user-friendly platform where car enthusiasts and clients can explore the wide range of premium services.

The new website, designed with a sleek, modern aesthetic, reflects the precision and craftsmanship that Red Box Restoration is known for. Visitors can easily navigate the website to learn more about the company’s services, including Paint Protection Film (PPF), custom vinyl wraps, paint correction, and more. Each service is detailed with clear descriptions, showcasing how Red Box Restoration brings a personal touch to every vehicle it works on.

Justin McClung, founder of Red Box Restoration, commented on the website launch: “We’re incredibly excited to unveil our new site to the public. It’s designed to give our customers a clear view of our services, highlighting our dedication to quality and attention to detail. We want the website to reflect our commitment to transforming every vehicle into a masterpiece.”

Key Features of the New Website:

–  Online Shopping Platform: A user-friendly e-commerce section where customers can purchase premium car care products, including sealants, cleaning kits, and more—all handpicked by Red Box Restoration’s certified specialists.

–  Detailed Service Pages: A comprehensive look at each custom restoration service available, from PPF and custom wraps to paint correction and professional detailing.

–  Gallery: Showcasing the exceptional craftsmanship of Red Box Restoration, featuring before-and-after images of some of the most impressive Red Box Restoration projects.

–  Client Testimonials: Real feedback from satisfied customers, reinforcing the company’s reputation as the go-to destination for car restoration and customization in Austin.

–  Streamlined Contact Form: An easy-to-use form for inquiries, making it more convenient than ever for clients to connect with the Red Box Restoration team.

The new website launch is part of Red Box Restoration’s ongoing effort to enhance the customer experience and make its elite services more accessible to clients throughout Austin and beyond. The site also includes an integrated blog section, where Red Box Restoration will provide insights and tips on maintaining and enhancing vehicle appearance and performance.

To explore the newly launched website, visit Red Box Restoration. The team invites visitors to experience firsthand the exceptional service and innovation that makes them Austin’s top choice for custom car restoration.

About Red Box Restoration

Red Box Restoration specializes in automotive restoration, customization, and protection services. With a focus on excellence, the shop offers high-end solutions including paint protection film, vinyl wraps, paint correction, and detailing. Located in Austin, Texas, Red Box Restoration is committed to transforming vehicles into extraordinary masterpieces, led by industry expert Justin McClung and his team of certified reconditioning specialists.

For media inquiries or more information, please contact below.

Media Contact
Company Name: Red Box Restoration
Contact Person: Justin McClung
Email: Send Email
Phone: 512-762-9069
Address:8408 Annalise Dr Suite 130
City: Austin
State: Texas 78744
Country: United States
Website: https://redbox-restoration.com/

Upgrade Home Office with the INNOCN 40-Inch Ultrawide Monitor – The Ideal Remote Work Companion

Shenzhen, China – October 7, 2024 – As remote work becomes the new normal, having the right tools is essential for productivity and comfort. The INNOCN 40-Inch WQHD Ultrawide Monitor (40C1R) is designed to transform your workspace. This monitor offers a stunning 3440 x 1440p resolution and a lightning-fast 144Hz refresh rate, ensuring that every task—from spreadsheets to video calls—looks and feels incredibly smooth. Now available for purchase in the US and Europe.

What sets this monitor apart is its premium ADS panel. It gives you an 18% larger viewable area compared to standard 34-inch monitors, which means you can see more details clearly, whether you’re working on spreadsheets, catching up on emails, or diving into a gaming session.

Thanks to AMD Free Sync Premium and HDR400 technology, your visuals will pop with vibrant colors and smooth images. With a brightness of 500 nits and a wide color gamut of 95% DCI-P3, everything you see on screen will be bright, clear, and lifelike.

Connecting your devices is super easy with the USB Type-C, DisplayPort, and HDMI ports. You can plug in your laptop, Mac, phone, or even your gaming consoles (like the PS5 and Xbox Series) without any fuss. Plus, it comes with a US power adapter for your convenience.

Comfort is key when you’re working long hours, and this monitor has adjustable features to help you find the perfect viewing angle. It tilts, swivels, and adjusts in height to suit your needs. Each INNOCN monitor also comes with a color calibration report, ensuring true-to-life colors. And with TÜV Rheinland certification for low blue light technology, you can enjoy hours of use without straining your eyes.

If multitasking is your thing, the PBP/PIP technology allows you to split the screen, making it easy to analyze data, edit photos and videos, or juggle multiple tasks all at once. You won’t miss a thing!

Special Pricing Alert!

• US Price: Regular Price: $549.99 | Prime Big Deal Price: $399.99 ($150 Off) | Valid: Oct 8 – Oct 9 | Check it out here

• EU Price: Regular Price: $499 | Best Deal Price: €399 (€100 Off) | Valid: Oct 8 – Oct 9 | Grab it here

In short, the INNOCN 40C1R Ultrawide Monitor is the perfect addition to your home office setup. It combines stunning visuals with the latest technology to keep you productive and entertained.

So, if you’re ready to take your workspace to the next level, check out INNOCN today!

Explore more of INNOCN’s latest innovations and offerings:

Prime Day Deals 2024: Deals Sheet

INNOCN Amazon Shop: https://amzn.to/4cQIze7

About INNOCN

Founded in 2014, INNOCN’s mission is to create elite monitors that deliver the best viewing experience. Leveraging extensive expertise in product design and visual display, INNOCN continually advances the monitor market with cutting-edge technology and innovation.

Media Contact:

Manufacturer’s Name: Shenzhen Century Joint Innovation Technology Company Limited (INNOCN)

Manufacturer’s Official Website: https://www.innocn.com

Manufacturer’s Email Address: marketing@innocn.com

Media Contact
Company Name: Shenzhen Century Joint Innovation Technology Company Limited
Contact Person: Media Relations
Email: Send Email
Country: China
Website: https://www.innocn.com

Upgrade the Gaming Setup with the INNOCN 27-Inch 240Hz Fast-IPS Monitor – Now at a Special Prime Big Deal Price

Shenzhen, China – October 7, 2024 – Next-gen consoles like the PS5 and Xbox Series X are pushing gaming to new heights, and to fully experience that, you need a monitor that can keep up. The INNOCN 27-Inch QHD 2K 1440P 240Hz Fast-IPS Gaming Monitor (27G1S Plus) is built for this. What makes it special? Well, this monitor doesn’t just look good—it delivers with a lightning-fast 240Hz refresh rate and 1ms response time. Translation? Incredibly smooth, fast-paced gameplay with zero lag, so you’re always in the action.

This monitor is also ahead of the curve with HDMI 2.1 support, meaning it’s ready to make the most out of the graphics and high frame rates next-gen consoles bring. But that’s just the start—what really sets it apart is the Fast-IPS panel. You’re getting vibrant, accurate colors combined with super quick response times. Plus, with a 2K QHD resolution (2560 x 1440P), the level of detail is amazing. Whether you’re exploring a fantasy world or racing through a cityscape, everything is crisp and vivid.

On top of that, you get HDR support and a 99% sRGB color gamut, so the range of colors and brightness levels will make everything feel more lifelike. And if you’re a PC gamer, the G-Sync compatibility is a game-changer—no more screen tearing or stuttering, just smooth, seamless gameplay. It’s perfect for those competitive moments when every frame counts.

But it’s not just about performance—the height-adjustable stand and VESA mount compatibility give you flexibility to set it up just how you like it. It’s great whether you’re gaming, streaming, or working.

The best part? Right now, you can snag the INNOCN 27G1S Plus for just $214.49 (down from $269.99) during Amazon’s Prime Big Deal on October 8 and 9. That’s a $55.50 discount for a top-tier gaming monitor that’ll take your setup to the next level.

At INNOCN, we believe that great gaming experiences start with the right gear. The 27G1S Plus is designed to give you the performance boost you need for the next generation of gaming.

Explore more of INNOCN’s latest innovations and offerings:

Product Link: 27G1S

Prime Day Deals 2024: https://bit.ly/4cw0erT

INNOCN Amazon Shop: https://amzn.to/4cQIze7

About INNOCN

Founded in 2014, INNOCN’s mission is to create elite monitors that deliver the best viewing experience. Leveraging extensive expertise in product design and visual display, INNOCN continually advances the monitor market with cutting-edge technology and innovation.

Media Contact:

Manufacturer’s Name: Shenzhen Century Joint Innovation Technology Company Limited (INNOCN)

Manufacturer’s Official Website: https://www.innocn.com

Manufacturer’s Email Address: marketing@innocn.com

Media Contact
Company Name: Shenzhen Century Joint Innovation Technology Company Limited
Contact Person: Media Relations
Email: Send Email
Country: China
Website: https://www.innocn.com